Evidence map›Paper›PMID 39820274›Full record

ArticleInflammatory bowel diseases2025

Expression Profile of MicroRNAs in Breast Milk of Women With Inflammatory Bowel Disease: Correlation With Disease Activity and Medical Treatments.

Regina Golan-Gerstl, Ami Ben Ya'acov, Mirit Musseri, Rosi Goldenberg, Yehudit Chammah, Tal Cherki, Shimon Reif, Ariella Bar Gil Shitrit

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Regina Golan-GerstlDepartment of Pediatrics, Hebrew University Hadassah Medical Center, Jerusalem, Israel.ORCID 0000-0003-3224-9495
Ami Ben Ya'acovDigestive Diseases Institute, Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Mirit MusseriDepartment of Pediatrics, Hebrew University Hadassah Medical Center, Jerusalem, Israel.
Rosi GoldenbergDigestive Diseases Institute, Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Yehudit ChammahDigestive Diseases Institute, Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Tal CherkiDigestive Diseases Institute, Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Shimon ReifDepartment of Pediatrics, Hebrew University Hadassah Medical Center, Jerusalem, Israel.
Ariella Bar Gil ShitritDigestive Diseases Institute, Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.

Funding

Israel Science FoundationKenneth Rainin Foundation
6 · The paper itself

Abstract

backgroundAlthough most inflammatory bowel disease (IBD) medications are considered safe during pregnancy, their impact on microRNAs (miRNAs) in breast milk is largely unknown. MiRNAs in milk, carried by milk-derived extracellular vesicles (MDEs), are transmitted to the newborn's gut to regulate genes. Aberrant miRNA expression profiles have been found in IBD within tissue, blood, and feces, but data on mother's milk are scarce.

methodsWe collected breast milk samples from 32 mothers with Crohn's disease (CD), 14 mothers with ulcerative colitis (UC), and 44 healthy controls. We analyzed miRNA expression through qualitative real-time polymerase chain reaction and Affymetrix miRNA chips. Target genes of differentially expressed miRNAs were predicted using miRATBase. Statistical analyses were conducted using GraphPad Prism software with Mann-Whitney tests.

resultsMilk-derived extracellular vesicles from mothers with IBD showed altered miRNA profiles compared to controls. Specifically, miR-21 and miR-320 were downregulated, while Let-7a was upregulated in IBD mothers. The expression patterns varied between CD and UC, with significantly lower MiR-21 in UC and higher Let-7a in CD. Additionally, anti-tumor necrosis factor treatment during pregnancy was associated with reduced miR-21 and miR-148a levels in MDEs. Pathway analysis revealed that these miRNAs are involved in immune regulation, particularly interleukin signaling pathways.

conclusionsThis study highlights that miRNAs in breast milk are differentially expressed in mothers with IBD, influenced by the disease and its treatments. These findings emphasize the impact of maternal health on milk composition and potential implications for infant immune development. Understanding these findings may guide personalized treatment strategies for mothers and promote breastfeeding among mothers with IBD.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesMicroRNAsMilk, HumanAdultCase-Control StudiesFemaleGene Expression ProfilingHumansPregnancyYoung AdultMicroRNAsbreast milkinflammatory bowel diseasemicroRNAmilk-derived vesicles

Identifiers

PMID39820274
PMCPMC11985391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.